• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        Tumor Vaccination with Cytokine-Encapsulated Microspheres

        互联网

        783
        The rapid advances that have taken place in tumor immunology within the past decade have fostered renewed interest in the use of immune-based therapies for the treatment of cancer (1 ,2 ). Numerous strategies, which aim to provoke and augment anti-tumor immunity in cancer patients, have been developed and are being tested in clinical trials (2 4 ). One strategy that has worked well in preclinical mouse models involves the use of immune stimulatory molecules, i.e., cytokines, to augment the anti-tumor activity of the immune system (5 7 ). The early studies focused on the systemic administration of selected cytokines to promote a nonspecific augmentation of an already existing anti-tumor immunity (5 ,7 ). While successful in murine models, particularly with interleukin (IL)-2 and -12, the systemic delivery of cytokines has not been efficacious in the clinics due to severe systemic toxicity. Systemic administration of immunotherapeutic agents ignores the paracrine nature of their activity. With the advent of molecular techniques that allowed efficient genetic modification of tumor cells in vitro, cytokine gene-modified tumor cell vaccines became the preferred alternative to systemic therapy. This approach results in the local and sustained release of cytokines by the tumor cells at the vaccine site, which induces the development of a tumor-specific, systemic anti-tumor immunity while circumventing the toxicity associated with systemic delivery (4 7 ).
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序